COST-UTILITY ANALYSIS OF TERIFLUNOMIDE IN NAIVE VS. PREVIOUSLY TREATED PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

被引：0

作者：

Lazzaro, C. ^{[1
]}

Bergamaschi, R. ^{[2
]}

Zaffaroni, M. ^{[3
]}

Totaro, R. ^{[4
]}

Paolicelli, D. ^{[5
]}

机构：

[1] Studio Econ Sanit, Milan, MI, Italy

[2] IRCCS Mondino Fdn, Pavia, Italy

[3] Hosp Gallarate, ASST Valle Olona, Multiple Sclerosis Ctr, Gallarate, Italy

[4] Osped San Salvatore, Ctr Malattie Demielinizzanti, Laquila, Italy

[5] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy

来源：

VALUE IN HEALTH | 2020年 / 23卷

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PND45

引用

页码：S631 / S631

页数：1

共 50 条

[1] Cost-utility analysis of teriflunomide in naive vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy
Lazzaro, Carlo
Bergamaschi, Roberto
Zaffaroni, Mauro
Totaro, Rocco
Paolicelli, Damiano
NEUROLOGICAL SCIENCES, 2022, 43 (08) : 4933 - 4944
[2] Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy
Carlo Lazzaro
Roberto Bergamaschi
Mauro Zaffaroni
Rocco Totaro
Damiano Paolicelli
Neurological Sciences, 2022, 43 : 4933 - 4944
[3] COST-UTILITY ANALYSIS OF DIMETHYL FUMARATE VERSUS FINGOLIMOD AND TERIFLUNOMIDE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA
Ordonez, J.
Serafini, P.
Machado, M.
VALUE IN HEALTH, 2016, 19 (07) : A434 - A434
[4] DIMETHYL FUMARATE VERSUS FINGOLIMOD AND TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA: A COST-UTILITY ANALYSIS
Ordonez, J. E.
VALUE IN HEALTH, 2017, 20 (05) : A194 - A194
[5] Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis
Chan, Andrew
de Seze, Jerome
Comabella, Manuel
CNS DRUGS, 2016, 30 (01) : 41 - 51
[6] Cost-Utility Analysis Comparing Ocrelizumab vs Rituximab in the Treatment of Relapsing-Remitting Multiple Sclerosis: The Colombian Perspective
Navarro, Cristian E.
Betancur, John E.
VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 83 - 91
[7] Dimethyl Fumarate demonstrates Cost-effectiveness vs Teriflunomide in Treatment-naive Patients with Relapsing-remitting Multiple Sclerosis in Sweden
Hernandez, L.
Toro-Diaz, H.
Cele, C.
Harrington, A.
Kinter, E.
Lundqvist, T.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 138 - 138
[8] Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
Imani, Ali
Golestani, Mina
IRANIAN JOURNAL OF NEUROLOGY, 2012, 11 (03) : 87 - 90
[9] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
Miller, Aaron E.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194
[10] Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis
Scott, Lesley J.
DRUGS, 2019, 79 (08) : 875 - 886

← 1 2 3 4 5 →